

Clinical trials of Vesnarinone

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
Vesnarinone vs placebo			
OPC-8212 MRG , 1990 n=45/48 follow-up: 3 months	Vesnarinone 60mg/d versus placebo	NYHA II-IV	Parallel groups double blind
VEST , 1998 n=2550/1283 follow-up: 9 months	Vesnarinone 30, 60mg/d versus placebo	NYHA III,IV	Parallel groups double blind
VSG , 1993 n=NA follow-up: 6 months	Vesnarinone 60mg/d versus placebo	NYHA II-IV	Parallel groups double blind

└ More details and results :

- phosphodiesterase III inhibitors for heart failure in all type of patients at <http://www.trialresultscenter.org/go-Q117>

References

OPC-8212 MRG, 1990:

A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. OPC-8212 Multicenter Research Group. Cardiovasc Drugs Ther 1990 Apr;4:419-25 [[2285626](#)]

VEST, 1998:

Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F 3rd, DeMets DL, White BG A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 1998 Dec 17;339:1810-6 [[9854116](#)]

VSG, 1993:

Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 1993 Jul 15;329:149-55 [[8515787](#)]

Entry terms: vesnarinone, vesnarinone, OPC 8212, OPC-8212,